

**(19) World Intellectual Property  
Organization  
International Bureau**



**(43) International Publication Date**  
**27 May 2004 (27.05.2004)**


**PCT**

**(10) International Publication Number**  
**WO 2004/043238 A2**

- (51) **International Patent Classification<sup>7</sup>:** **A61B** MI 48084 (US). **CHRISTNER, Robert** [US/US]; 2262 Parkwood Avenue, Toledo, OH 43620 (US).
- (21) **International Application Number:** PCT/US2003/036120 (74) **Agents:** **BENT, Stephen, A.** et al.; **Foley & Lardner**, Washington Harbour, Suite 500, 3000 "K" Street, N.W., Washington, DC 20007-5101 (US).
- (22) **International Filing Date:** 13 November 2003 (13.11.2003) (81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:** 60/426,096 14 November 2002 (14.11.2002) US (84) **Designated States (regional):** ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) **Applicant (for all designated States except US):** **CIPHER-GEN BIOSYSTEMS, INC.** [US/US]; 6611 Dumbarton Circle, Freemont, CA 94555 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **BUHIMSCHI, Irina, A.** [US/US]; 2728 Alisop Place, Apt. 309, Troy,

*[Continued on next page]*

**(54) Title:** BIOMARKERS FOR INTRO-AMINIOTIC INFLAMMATION



**(S7) Abstract:** Biomarkers have been discovered that are capable of identifying intra-amniotic inflammation. A single biomarker or combination of biomarkers can be used to qualify the risk of preterm delivery in a patient, provided that at least one of the biomarkers is a calgranulin, preferably calgranulin A or C. The result is a rapid and reliable proteomic approach to identifying intra-amniotic inflammation. In particular, the concentrations of the biomarkers correlate with the magnitude of intra-amniotic inflammation and, hence, of preterm delivery.

**WO 2004/043238 A2**